Viemed Healthcare Announces Third Quarter 2025 Financial Results
LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home...
Epidemics
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
VSee Health Accelerates Teleradiology Domination
100K+ READS IN 6 MONTHS, FULL ROLLOUT TO 35 HOSPITALS BY YEAR-END - PRIME TIME FOR INVESTORS IN A $455B...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
HCA Healthcare Reports Third Quarter 2025 Results
Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended...
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in...
Vireo Growth Inc. Announces Closing of Acquisition of Outstanding Senior Secured Convertible Notes of Schwazze
– Parties enter into Restructuring Support Agreement; Vireo to bid to acquire control of Schwazze assets – – Schwazze operates...
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer...
OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance
Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlookWARSAW, Ind., Oct. 09,...
NHI Announces $74.3 Million SHOP Investment
MURFREESBORO, TN / ACCESS Newswire / October 2, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has...
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology...
Viemed Healthcare Announces Completion of Share Repurchase Program
LAFAYETTE, LA / ACCESS Newswire / September 23, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national...
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF”...
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab...